Title |
Primary prophylactic colony‐stimulating factors for the prevention of chemotherapy‐induced febrile neutropenia in breast cancer patients
|
---|---|
Published in |
Cochrane database of systematic reviews, October 2012
|
DOI | 10.1002/14651858.cd007913.pub2 |
Pubmed ID | |
Authors |
Peter Renner, Stefania Milazzo, Jian Ping Liu, Marcel Zwahlen, Josef Birkmann, Markus Horneber |
Abstract |
High-dose or dose-intensive cytotoxic chemotherapy often causes myelosuppression and severe neutropenia among cancer patients. Severe neutropenia accompanied by fever, named febrile neutropenia (FN), is the most serious manifestation of neutropenia usually requiring hospitalization and intravenous antibiotics. FN and neutropenia can lead to chemotherapy treatment delays or dose reductions, which potentially compromises the effectiveness of cancer treatment and prospects for a cure. Granulocyte-macrophage (GM) and granulocyte colony-stimulating factors (G-CSFs) are administered during chemotherapy in order to prevent or reduce the incidence or the duration of FN and neutropenia. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Canada | 1 | <1% |
Unknown | 184 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 23 | 12% |
Student > Master | 20 | 11% |
Student > Bachelor | 18 | 10% |
Student > Ph. D. Student | 12 | 6% |
Other | 11 | 6% |
Other | 34 | 18% |
Unknown | 67 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 56 | 30% |
Nursing and Health Professions | 17 | 9% |
Biochemistry, Genetics and Molecular Biology | 11 | 6% |
Agricultural and Biological Sciences | 4 | 2% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 2% |
Other | 21 | 11% |
Unknown | 72 | 39% |